⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for IFM 99-02 Thalidomide in Myeloma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: IFM 99-02 Thalidomide in Myeloma

Official Title:

Study ID: NCT00222053

Study Description

Brief Summary: Principal objective is to evaluate the impact of Thalidomide to prolong the duration of response after autologous transplantation for myeloma

Detailed Description:

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Médecine Interne, CHU Purpan, Toulouse, , France

Médecine Interne, Hôpital Rangueil, Toulouse, , France

Rhumatologie, CHU Purpan, Toulouse, , France

Rhumatologie, CHU Rangueil, Toulouse, , France

Service d'hématologie, CHU Purpan, Toulouse, , France

Contact Details

Name: ATTAL Michel, MD

Affiliation: CHU Toulouse

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: